Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Elise Truchetet

Showing results (1-10 of 169) with videos related to

Pageof 17
Sort By:
Seminars in Immunology|March 19, 2018
Re-thinking our understanding of immunity: Robustness in the tissue reconstruction systemMarie-Elise Truchetet, Thomas Pradeu
Expert Opinion on Pharmacotherapy|June 26, 2020
What value do JAK inhibitors have in treating rheumatoid arthritis?Christophe Richez, Marie-Elise Truchetet
Expert Opinion on Pharmacotherapy|August 17, 2021
Evaluating filgotinib for the treatment of rheumatoid arthritisChristophe Richez, Marie-Elise Truchetet
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
ReplyMarie-Elise Truchetet, Thierry Schaeverbeke
Rheumatology (Oxford, England)|December 10, 2019
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapyMarie Kostine, Marie-Elise Truchetet, Thierry Schaeverbeke
Journal of Clinical Medicine|April 23, 2022
Strategy and Challenges of Paraclinical Examinations in Adult-Onset Still's DiseaseNicolas Poursac, Itsaso Odriozola, Marie-Elise Truchetet
Joint Bone Spine|June 29, 2013
Gut metagenome and spondyloarthritisThierry Schaeverbeke, Marie-Elise Truchetet, Christophe Richez
Rheumatology (Oxford, England)|October 5, 2017
Serum sickness-like disease after switching to biosimilar infliximabMarc Scherlinger, Thierry Schaeverbeke, Marie-Elise Truchetet, et al.
Biomed Research International|August 29, 2013
IL-17 in the rheumatologist's line of sightMarie-Elise Truchetet, M Djavad Mossalayi, Katia Boniface
Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2017
Are Murine Fibroblasts Responsible for Fibrosis Reversion? Comment on the Article by Luchetti et alPauline Henrot, Marie-Elise Truchetet, Muriel Cario-Andre
Pageof 17

Showing results (1-10 of 169) with videos related to

Sort By:
Pageof 17
Seminars in Immunology|March 19, 2018
Re-thinking our understanding of immunity: Robustness in the tissue reconstruction systemMarie-Elise Truchetet, Thomas Pradeu
Expert Opinion on Pharmacotherapy|June 26, 2020
What value do JAK inhibitors have in treating rheumatoid arthritis?Christophe Richez, Marie-Elise Truchetet
Expert Opinion on Pharmacotherapy|August 17, 2021
Evaluating filgotinib for the treatment of rheumatoid arthritisChristophe Richez, Marie-Elise Truchetet
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
ReplyMarie-Elise Truchetet, Thierry Schaeverbeke
Rheumatology (Oxford, England)|December 10, 2019
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapyMarie Kostine, Marie-Elise Truchetet, Thierry Schaeverbeke
Journal of Clinical Medicine|April 23, 2022
Strategy and Challenges of Paraclinical Examinations in Adult-Onset Still's DiseaseNicolas Poursac, Itsaso Odriozola, Marie-Elise Truchetet
Joint Bone Spine|June 29, 2013
Gut metagenome and spondyloarthritisThierry Schaeverbeke, Marie-Elise Truchetet, Christophe Richez
Rheumatology (Oxford, England)|October 5, 2017
Serum sickness-like disease after switching to biosimilar infliximabMarc Scherlinger, Thierry Schaeverbeke, Marie-Elise Truchetet, et al.
Biomed Research International|August 29, 2013
IL-17 in the rheumatologist's line of sightMarie-Elise Truchetet, M Djavad Mossalayi, Katia Boniface
Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2017
Are Murine Fibroblasts Responsible for Fibrosis Reversion? Comment on the Article by Luchetti et alPauline Henrot, Marie-Elise Truchetet, Muriel Cario-Andre
Pageof 17